NCT05467670 - Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2031

Conditions

Ovarian Cancer

Interventions

DRUG

Pembrolizumab

A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.

DRUG

ALX148

A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.

DRUG

Doxorubicin

An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh